Paratek Pharmaceuticals, Inc. (PRTK)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.8400+0.0700 (+1.47%)
At close: 4:00PM EDT
| Previous close | 4.7700 |
| Open | 4.7700 |
| Bid | 4.8100 x 1000 |
| Ask | 5.3000 x 800 |
| Day's range | 4.7000 - 4.8500 |
| 52-week range | 4.5100 - 11.2400 |
| Volume | 172,126 |
| Avg. volume | 453,123 |
| Market cap | 227.075M |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1850 |
| Earnings date | 24 Feb 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 31 Oct 2014 |
| 1y target est | 21.75 |
- Zacks
Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM
The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.
- Simply Wall St.
What Percentage Of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Shares Do Insiders Own?
The big shareholder groups in Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) have power over the company. Large...
- Motley Fool
Paratek Pharmaceuticals (PRTK) Q2 2021 Earnings Call Transcript
Thank you, operator, and good afternoon, everyone, and welcome to Paratek's second-quarter 2021 earnings and corporate update conference call. Participants on today's call are Evan Loh, chief executive officer; Adam Woodrow, president and chief commercial officer; and Randy Brenner, chief development and regulatory officer.
© 2021 Verizon Media. All rights reserved.
